Zur Seitennavigation oder mit Tastenkombination für den
accesskey
-Taste und Taste 1
Zum Seiteninhalt oder mit Tastenkombination für den
accesskey
und Taste 2
S
tartseite
A
nmelden
Hilfe
Sitemap
Impressum
Datenschutz
node2
Studentisches Leben
Veranstaltungen
Einrichtungen
Räume und Gebäude
Personen
Forschung
Startseite
Publikationen
Projekte
Promotionen/Habilitationen
Publikationen
Navigation ausblenden
Publikation: Zeitschriftenartikel
In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis
Grunddaten
Abstract
Autoren
Einrichtungen
Grunddaten
Titel
In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis
Erscheinungsjahr
2024
Seiten (von – bis)
1 – 11
Band
31
Heft-Nr.
4
Jahr
2024
Publikationsform
Elektronische Ressource
Publikationsart
Zeitschriftenartikel
Sprache
Englisch
DOI
10.1111/ene.16204
Letzte Änderung
15.05.2024 06:02:00
Bearbeitungsstatus
durch UB Rostock abschließend validiert
Dauerhafte URL
http://purl.uni-rostock.de/fodb/pub/71623
Links zu Katalogen
Abstract
Background and purpose: In 2016, we concluded a randomized controlled trial testing 1mg rasagiline per day add-on to standard therapy in 252 amyotrophic lateral sclerosis (ALS) patients. This article aims at better characterizing ALS patients who could possibly benefit from rasagiline by reporting new subgroup analysis and genetic data. Methods: We performed further exploratory in-depth analyses of the study population and investigated the relevance of single nucleotide polymorphisms (SNPs) related to the dopaminergic system. Results: Placebo-treated patients with very slow disease progression (loss of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised [ALSFRS-R] per month before randomization of 0.328 points) showed a per se survival probability after 24months of 0.85 (95% confidence interval=0.65-0.94). The large group of intermediate to fast progressing ALS patients showed a prolonged survival in the rasagiline group compared to placebo after 6 and 12months (p=0.02, p=0.04), and a reduced decline of ALSFRS-R after 18months (p=0.049). SNP genotypes in the MAOB gene and DRD2 gene did not show clear associations with rasagiline treatment effects. Conclusions: These results underline the need to consider individual disease progression at baseline in future ALS studies. Very slow disease progressors compromise the statistical power of studies with treatment durations of 12-18months using clinical endpoints. Analysis of MAOB and DRD2 SNPs revealed no clear relationship to any outcome parameter. More insights are expected from future studies elucidating whether patients with DRD2CC genotype (Rs2283265) show a pronounced benefit from treatment with rasagiline, pointing to the opportunities precision medicine could open up for ALS patients in the future.
Autoren
Schuster, Joachim
Dreyhaupt, Jens
Mönkemöller, Karla
Dupuis, Luc
Dieterlé, Stéphane
Weishaupt, Jochen H.
Kassubek, Jan Rainer
Petri, Susanne
Meyer, Thomas
Großkreutz, Julian
Emmer, Alexander
Herrmann, Andreas
Prudlo, Johannes
Einrichtungen
UMR/Klinik und Poliklinik für Neurologie (KN)
UMR/KN/Sektion für Translationale Neurogeneration "Albrecht Kossel"